Recent 8-K filings for REGN

• April 29, 2026, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut

  Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.

• April 8, 2026, 7:59 PM ET earnings materiality 0.60 negative item 2.02 ◈ Earnings Releases

  Regeneron expects ~$102M IPR&D charge in Q1 2026, ~$0.81 EPS hit

  Pre-tax acquired IPR&D charge of ~$102M from milestone/up-front payments and equity securities premium.

• January 30, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Regeneron Q4 rev $3.88B (+3%), GAAP EPS $7.86; Dupixent +34% to $4.9B

  Q4 2025 total revenue $3.884B (+3% YoY); GAAP diluted EPS $7.86 (vs $8.06 Q4 2024); non-GAAP EPS $11.44 (vs $12.07).

• October 28, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%

  Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).

• August 1, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%

  Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).

• April 29, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Regeneron Q1 revenue down 4%, non-GAAP EPS falls 14%; lowers gross margin guidance

  Q1 2025 revenue $3.03B (-4% YoY); GAAP EPS $7.27 (+16%), non-GAAP EPS $8.22 (-14%).

• February 4, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 8.01item 9.01

  Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback

  Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).

• January 13, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 7.01item 9.01

  Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates

  EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).

• October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%

  Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).

• August 1, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD

  Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback

  GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

4 positive 5 negative 8 neutral

source · REGN on sec.gov